Bio-Rad highlights its ddPCR leadership in oncology at AMP 2024, showcasing new products, IVDR certification, and collaborations in MRD.
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced updates on its oncology assay portfolio and regulatory milestones, ahead of its presence at the AMP 2024 meeting. Centered around improving patient outcomes through cancer biomarker detection, and based on Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology, updates include achieving IVDR Class C certification for its QXDx BCR-ABL %IS Kit (IVD/CE-IVD), to monitor patients with Chronic Myeloid Leukemia (CML), as well as strategic collaborations with leaders in the fields of molecular residual disease (MRD) detection and circulating tumor DNA (ctDNA) analysis in oncology.
Products to Support the Adoption of Droplet Digital PCR in Oncology
In a key regulatory milestone, Bio-Rad has obtained In Vitro Diagnostic Regulation (IVDR) certification for its ddPCR QXDx BCR-ABL test in Europe by the notified body GMED (0459). Reporting in both International Scale (%IS) and Molecular Response (MR) values, the QXDx BCR-ABL %IS Kit monitors the p210 BCR-ABL major translocation in the peripheral blood of patients with CML. The test is the first FDA-cleared CML monitoring assay for BCR-ABL designed to run on Bio-Rad's QXDx ddPCR System, enabling laboratories with precise, highly sensitive, direct absolute quantification of nucleic acids. Monitoring of BCR-ABL transcript levels gives an indication of leukemic inhibition throughout treatment in CML patients.
In July 2024, Bio-Rad launched more than 50 new ddPCR Methylation Detection Assays, available on the Company's Digital Assays portal, designed to provide more precise and reliable detection of methylation markers that are critical tools in the research of early diagnosis and monitoring of various cancers. This builds upon Bio-Rad’s extensive library of thousands of oncology-specific assays developed for Droplet Digital PCR, which have supported hundreds of published peer-reviewed studies, supporting the Company’s strategy to help advance oncology research.
Collaborations Leveraging Droplet Digital PCR
MRD monitoring of cancer provides an indication of both remission and potential relapse and is being increasingly adopted for the monitoring of solid tumors. Bio-Rad is collaborating with Allegheny Health Network (AHN), an integrated health network with 14 hospitals, in an observational study using ddPCR for tumor-informed MRD monitoring in patients with solid-tumor cancer following curative-intent treatment. Bio-Rad's QX600™ ddPCR System offers investigators unmatched sensitivity, precision, and absolute quantification capabilities, and can be used to detect disease markers, such as ctDNA, earlier and more precisely than other commonly used technologies. Bio-Rad is also collaborating with the Department of Molecular Medicine (MOMA) at Aarhus University Hospital in Denmark, to generate evidence for MRD monitoring post curative-intent treatment in patients with colorectal cancer.
Under a longstanding collaboration between Bio-Rad and Biodesix, a diagnostics solutions company with a focus on lung diseases, novel, highly multiplexed ddPCR oncology assays are being developed for future commercialization. Biodesix recently announced its use of ddPCR in the evolution of its collaborative research agreement with the Memorial Sloan Kettering Cancer Center, driving forward advancements in cancer diagnostics and treatment. Droplet Digital PCR performed at Biodesix was recently featured in two publications, in The New England Journal of Medicine, and Annals of Oncology, related to Johnson and Johnson’s MARIPOSA non-small-cell lung cancer trial, where it was used to measure cancer mutations in participating patient samples.
Bio-Rad will host thought-leaders from these collaborating organizations at its workshop at AMP 2024 focusing on MRD and Droplet Digital PCR. Hosted by Dr. Prithwish Pal, Director, Global Product Marketing, Oncology at Bio-Rad, both Dr. William LaFramboise, Chief Genomics Technology Officer at AHN, and Dr. Gary Pestano, Chief Development Officer at Biodesix, Inc., will discuss their work in the development of highly sensitive mutation detection and ctDNA analysis assays. Discussions will include how these applications are changing the field of MRD detection in oncology and why Droplet Digital PCR, which affords high precision along with a cost-effective, user-friendly workflow, has been critical to their work.
"Bio-Rad continues to build its leadership position in the oncology market," said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories. "We are extremely proud that our BCR-ABL assay has already obtained IVDR certification, alongside key product launches earlier in the year including the first ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection in clinical research, the ddPLEX ESR1 Mutation Detection Kit." He continues: "We are accelerating further progress through our strategic collaborations outlined above, and through our involvement in high-profile consortia, such as BloodPAC and the FNIH Biomarkers consortium. We are justifiably extremely proud of our progress in this vital area of science and look forward to meeting with our colleagues in the oncology field at AMP."
To learn more about Bio-Rad's QXDx BCR-ABL %IS Kit, visit bio-rad.com/IVDR/BCR-ABL.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Katrina_academia@bio-rad.com
Zyme Communications
Dr. Maria Spyrou
+44 (0) 7707 049 640
maria.spyrou@zymecommunications.com